Greenup Street Wealth Management LLC acquired a new stake of 19,408 shares in Gilead Sciences, Inc. valued at approximately $2.38 million during the fourth quarter. This acquisition is part of broader institutional investment, with several other firms also adjusting their positions in Gilead, which now sees institutional investors and hedge funds owning 83.67% of the company's stock. The biopharmaceutical company recently reported strong quarterly earnings, beating revenue and EPS estimates, raised its quarterly dividend, and is actively expanding into oncology through acquisitions and licensing agreements.

Greenup Street Wealth Management LLC significantly increased its stake in General Dynamics Corporation during Q4, buying 5,538 shares to hold a total of 6,207 shares valued at $2.09 million. This occurred as General Dynamics exceeded Q4 earnings expectations with EPS of $4.17 and revenue of $14.38 billion, also raising its quarterly dividend. Despite insider selling, analysts maintain a "Moderate Buy" rating for the stock.

HF Advisory Group LLC significantly increased its stake in General Mills (GIS) by 299.0% in Q4, acquiring 36,401 additional shares. Despite this, analyst sentiment remains weak, with multiple firms cutting price targets and ratings, and the stock is down about 21% year-to-date due to weak consumer demand and margin pressures. General Mills has declared a quarterly dividend of $0.61, offering a 6.9% yield, but recent quarterly results missed analyst expectations for EPS and revenue.

AbbVie announced positive Phase 2 trial results for its ovarian cancer drug, mirvetuximab soravtansine-gynx, when combined with carboplatin, showing a 62.7% objective response rate in platinum-sensitive patients. The combination therapy demonstrated a median duration of response of 11.2 months and a consistent safety profile. Despite these promising results, the drug combination is not yet approved in major territories, though the monotherapy is approved for platinum-resistant cases.

Sumitomo Mitsui Trust Group Inc. reduced its stake in Adobe Inc. by 17.3%, selling 238,867 shares and now holding 1,140,262 shares valued at approximately $399.08 million. This sale comes despite Adobe beating Q1 earnings and revenue expectations and reaffirming its FY 2026 guidance. The stock, however, faces pressure from AI competition concerns, analyst downgrades, and leadership transition chatter, leading to a "Hold" consensus rating and a recent 52-week low.

Robeco Institutional Asset Management B.V. increased its stake in Adobe Inc. by 2.8% in Q4, acquiring 21,914 additional shares and bringing its total holdings to 793,898 shares valued at $277.9 million. This move comes as Adobe reported strong Q1 results, beating EPS and revenue estimates, and reaffirmed its FY 2026 guidance. Despite this, analyst sentiment remains mixed due to AI competition concerns, with the stock hitting a 52-week low.

Sumitomo Mitsui Trust Group Inc. reduced its stake in Caterpillar Inc. by 8.5% in the fourth quarter, selling 125,872 shares to hold a total of 1,352,474 shares valued at $774.8 million. Despite this, Caterpillar reported strong Q4 results, exceeding revenue and EPS expectations, and announced a quarterly dividend of $1.51. Analysts currently maintain a "Moderate Buy" consensus rating with a price target of $741.68, though concerns about high valuation and cyclical exposure persist.

Palouse Capital Management Inc. has initiated a new position in Honeywell International Inc. by acquiring 9,443 shares valued at approximately $1.84 million in the fourth quarter. This move is part of a trend where several institutional investors have significantly increased their holdings in Honeywell, leading to institutional ownership of about 75.91%. Honeywell has demonstrated strong financial performance, beating Q4 expectations with $2.59 EPS and $10.07 billion in revenue, and analysts currently rate the stock as a "Moderate Buy" with a target price of $251.83.

Sumitomo Mitsui Trust Group Inc. reduced its stake in Merck & Co., Inc. by 5.4% in the fourth quarter, now holding 6,971,801 shares valued at approximately $733.85 million. Despite this reduction, other institutional investors significantly increased their positions in Merck, and analysts maintain a "Moderate Buy" consensus rating with an average target price of $127.59. Merck reported strong Q4 earnings, beating estimates, and announced a $3.40 annual dividend, while insider transactions showed some share sales.

Cambiar Investors LLC reduced its holdings in SLB Limited by 3.4% during Q4 2025, selling 47,436 shares and bringing its total stake to 1.33 million shares valued at $51 million. This portfolio adjustment reflects the firm's ongoing strategy and provides insight into investor sentiment regarding the oil and gas industry. SLB now constitutes 2.3% of Cambiar's overall portfolio and is its 17th largest holding.